Therapeutic Efficiency of Multiple Applications of Magnetic Hyperthermia Technique in Glioblastoma Using Aminosilane Coated Iron Oxide Nanoparticles: In Vitro and In Vivo Study
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Magnetic hyperthermia (MHT) has been shown as a promising alternative therapy for glioblastoma (GBM) treatment. This study consists of three parts: The first part evaluates the heating potential of aminosilane-coated superparamagnetic iron oxide nanoparticles (SPIONa). The second and third parts comprise the evaluation of MHT multiple applications in GBM model, either in vitro or in vivo. The obtained heating curves of SPIONa (100 nm, +20 mV) and their specific absorption rates (SAR) stablished the best therapeutic conditions for frequencies (309 kHz and 557 kHz) and magnetic field (300 Gauss), which were stablished based on three in vitro MHT application in C6 GBM cell line. The bioluminescence (BLI) signal decayed in all applications and parameters tested and 309 kHz with 300 Gauss have shown to provide the best therapeutic effect. These parameters were also established for three MHT applications in vivo, in which the decay of BLI signal correlates with reduced tumor and also with decreased tumor glucose uptake assessed by positron emission tomography (PET) images. The behavior assessment showed a slight improvement after each MHT therapy, but after three applications the motor function displayed a relevant and progressive improvement until the latest evaluation. Thus, MHT multiple applications allowed an almost total regression of the GBM tumor in vivo. However, futher evaluations after the therapy acute phase are necessary to follow the evolution or tumor total regression. BLI, positron emission tomography (PET), and spontaneous locomotion evaluation techniques were effective in longitudinally monitoring the therapeutic effects of the MHT technique.
Han H, Du A, Li J, Han H, Feng P, Zhu Y Oncol Rep. 2025; 53(4).
PMID: 40017136 PMC: 11894601. DOI: 10.3892/or.2025.8881.
Rajan A, Laha S, Sahu N, Thorat N, Shankar B Mater Today Bio. 2024; 29:101348.
PMID: 39669801 PMC: 11636219. DOI: 10.1016/j.mtbio.2024.101348.
Munoz J, Pileggi G, Penteado Nucci M, Alves A, Pedrini F, Valle N Pharmaceutics. 2024; 16(9).
PMID: 39339193 PMC: 11434665. DOI: 10.3390/pharmaceutics16091156.
Magnetic Hyperthermia in Glioblastoma Multiforme Treatment.
Manescu Paltanea V, Antoniac I, Paltanea G, Nemoianu I, Mohan A, Antoniac A Int J Mol Sci. 2024; 25(18).
PMID: 39337552 PMC: 11432100. DOI: 10.3390/ijms251810065.
Rentzeperis F, Rivera D, Zhang J, Brown C, Young T, Rodriguez B Micromachines (Basel). 2024; 15(5).
PMID: 38793132 PMC: 11123314. DOI: 10.3390/mi15050559.